Hasil Pencarian  ::  Simpan CSV :: Kembali

"Penelitian survival secara historical cohort pada enam puluh dua penderita tumor ovarium borderline. Terdapat 9 penderita stadium FIGO IA, 9 stadium IC, 3 stadium IIIA, 2 stadium IIIB, 4 stadium IIIC, 1 stadium IV dan 34 stadium inadekuat. Dua puluh satu penderita dilakukan pembedahan radikal, 10 penderita hanya dilakukan histerektomi total dan salfingo-ooforektomi bilateral, 6 penderita dilakukan pembedahan konservatif, 24 penderita hanya dilakukan unilateral salfingo-ooforektomi atau kistektomi dan 1 penderita hanya biopsi saja. Enam belas penderita mendapat kemoterapi adjuvan kombinasi dengan platinum base, yaitu 8 penderita stadium inadekuat, 7 stadium III dan 1 stadium IV. Lama pengamatan lanjut antara 0,002 sampai 10,48 tahun dengan median 3,5 tahun. Lima puluh sembilan penderita tetap hidup. Tiga penderita meninggal karena penyakitnya. Residif terjadi pada 4 penderita. Ketahanan hidup penderita 2 tahun 96% dan 10 tahun 94%. Pada test ?log rank? didapatkan residu dan tipe histologi merupakan faktor prognostik yang bermakna mempengaruhi survival. (Med J Indones 2002; 11: 222-9)

---

Sixty-two patients with borderline tumors of ovary were historical cohort analyzed for survival characteristics. There were 9 patients with FIGO stage IA, 9 with stage IC, 3 with stage IIIA, 2 with stage IIIB, 4 with stage IIIC, 1 with stage IV and 34 with inadequate stage tumors. Twenty one patients had surgical staging with radical surgery, 10 patient had at least a total abdominal hysterectomy and bilateral salpingo-oophorectomy, 6 patient had surgical staging with conservative surgery, 24 patient had at least a unilateral salphingo-oophorectomy or ovarian cystectomy and 1 patient had biopsy. Sixteen patients received cisplatin-based combination chemotherapy, that were 8 with inadequate stage tumors, 7 with stage III tumors and 1 with stage IV tumor. Follow-up range from 0.02 to 10.48 years, with a median of 3.5 years. Fifty nine patient were alive. Three patients died, all of disease. Recurrence were found in 4 patients. The overall 2-years survival rate was 96% and 10-years survival rate was 94%. In log rank test, residual disease and histology type were significant predictor of survival. (Med J Indones 2002; 11:222-9)"

"Latar belakang: Kesintasan 5 tahun tumor ovarium borderline pada stadium awal cukup baik, sekitar 95-100%. Tatalaksana dari tumor ini adalah dengan pembedahan, pada pasien yang masih ingin mempertahankan fungsi reproduksinya, operasi sebisanya dilakukan dengan tetap meninggalkan uterus dan satu ovariumnya. Kemoterapi tidak dianjurkan untuk tumor ovarium borderline stadium awal. Di Indonesia penelitian tentang kesintasan tumor ovarium borderline masih sangat terbatas, oleh karena itu diperlukan penelitian lebih lanjut. Tujuan: Untuk mengetahui kesintasan tumor ovarium borderline di RSCM. Metode: Studi ini merupakan studi analitik deskriptif. Pasien yang didiagnosis dan dilakukan pembedahan di Departemen Obstetri dan Ginekologi RSCM pada periode Januari 2008-Desember 2010 dengan hasil histopatologi tumor ovarium borderline, di follow up untuk mengetahui kesintasan selama 5 tahun.Hasil: Subyek penelitian didapat 42 orang. Hasil kesintasan tumor ovarium borderline didapat sebesar 97,6%. Pada penelitian ini faktor umur, paritas, riwayat keluarga dan kontrasepsi oral, CA 125, asites, dan tindakan pembedahan didapatkan tidak mempunyai hubungan yang konsisten dengan tumor ovarium borderline. Jenis histopatologi yaitu tumor ovarium borderline serosum dan tatalaksana pembedahan tanpa dilanjutkan tindakan kemoterapi mempengaruhi kesintasan tumor ovarium borderline di RSCM dengan nilai p = 0,000 dan p = 0,001.Kesimpulan: Kesintasan 5 tahun penderita tumor ovarium borderline yang ditatalaksana di RSCM cukup baik. Tatalaksananya dititikberatkan pada pasien dengan jenis histopatologi serosum karena faktor ini mempengaruhi kesintasan 5 tahun pasien tumor ovarium borderline dan tanpa tindakan lanjutan kemoterapi hasilnya cukup baik.

---

Background: Five years survival of ovarian borderline tumors at early stage is quite good, about 95-100%. The procedures of this tumor is surgery, for patients who still want to maintain reproductive function, the best procedure by leaving the uterus and ovary. Chemotherapy is not recommended for early-stage borderline ovarian tumors. In Indonesia research on borderline ovarian tumors is limited, therefore more research is needed.Objective: To determine survival of ovarian borderline tumors in RSCM Hospital. Methode: This study is a descriptive analytic. Patients were diagnosed and surgery at Department of Obstetrics and Gynaecology RSCM on January 2008-December 2010 with a borderline ovarian tumor histopathology results, in the follow-up to determine the survival rate for 5 years, simple random sampling. Analysis of survival use Kapplan Meier Analysis.Result: The study gained 42 patients. Borderline ovarian tumor survival results obtained for 97.6%. In this study, age, parity, family history and oral contraceptive, CA 125, surgery, ascites have no consistent relationship with a borderline ovarian tumor's survival. Histopathology and chemotherapy have consistent relationship with p = 0,000 and p = 0,001.Discussion: Five years survival of patients with borderline ovarian tumors were administered in RSCM is good. It is important to pay attention to histopathology result and patient have a good survival without chemotherapy."

"ABSTRAKLatar Belakang. Terdapat gangguan sistem imun pada sepsis. Fase awal ditandaidengan hiperinflamasi, sedangkan fase lanjut ditandai dengan imunosupresi.Kematian kumulatif lebih banyak pada fase lanjut. Saat ini belum terdapatpenelitian yang secara khusus meneliti faktor prognostik mortalitas sepsis faselanjut dan mengembangkan model prediksi mortalitasnya.Tujuan. Mengetahui faktor prognostik mortalitas sepsis berat fase lanjut di ICUdan mengembangkan sistem skor untuk memprediksi mortalitas.Metode. Penelitian kohort retrospektif dilakukan pada pasien dewasa yangmengalami sepsis berat di ICU RSCM pada periode Oktober 2011 – November2012 dan masih bertahan setelah > 72 jam diagnosis sepsis ditegakkan di ICU.Tujuh faktor prognostik diidentifikasi saat diagnosis sepsis berat ditegakkan diICU. Prediktor independen diidentifikasi dengan analisis Cox’s proportionalhazard. Prediktor yang bermakna secara statistik dikuantifikasi dalam modelprediksi. Kalibrasi model dinilai dengan uji Hosmer-Lemeshow dan kemampuandiskriminasi dinilai dari area under curve (AUC) dari receiver operating curve.Hasil. Subjek penelitian terdiri atas 220 pasien. Mortalitas 28 hari sepsis beratfase lanjut adalah 40%. Faktor prognostik yang bermakna adalah alasan masukICU (medis (HR 2,75; IK95%:1,56-4,84), pembedahan emergensi (HR 1,96;IK95%:0,99 – 3,90), indeks komorbiditas Charlson > 2 (HR 2,07; IK95%:1,32-3,23), dan skor MSOFA > 4 (HR 2,84; IK95%:1,54-5,24). Model prediksimemiliki kemampuan diskriminasi yang baik (AUC 0,844) dan kalibrasi yangbaik (uji Hosmer-Lemeshow p 0,674). Berdasarkan model tersebut risikomortalitas dapat dibagi menjadi rendah (skor 0, mortalitas 5,4%), sedang (skor 1 –2,5, mortalitas 20,6%), dan tinggi (skor > 2,5, mortalitas 73,6%).Simpulan. Alasan masuk medis dan pembedahan emergensi, indeks komorbiditasCharlson > 2, dan skor MSOFA > 4 merupakan faktor prognostik mortalitassepsis berat fase lanjut di ICU RSCM. Sebuah model telah dikembangkan untukmemprediksi dan mengklasifikasikan risiko mortalitas.

---

ABSTRACTBackground. Immune system derrangement occurs during the course of sepsis,characterized by hyperinflamation in early phase and hypoinflamation andimmunosupression in late phase. The number of patient die during late phase islarger than early phase. Until now, there is no study specifically addressingprognostic factors of mortality from late sepsis and developing a mortalityprediction model.Aim. To determine prognostic factors of mortality from late phase of severesepsis in ICU and to develop scoring system to predict mortality.Method. A retrospective cohort study was conducted to identify prognosticfactors associated with mortality. Adult patients admitted to ICU duringNovember 2011 until October 2012 who developed severe sepsis and still alivefor minimum 72 hours were included in this study. Seven predefined prognosticfactors were indentified at the onset of severe sepsis in ICU. Cox’s proportionalhazard ratio was used to identify independent prognostic factors. Eachindependent factors was quantified to develop a prediction model. Calibration ofthe model was tested by Hosmer-Lemeshow, and its discrimination ability wascalculated from area under receiver operating curve.Result. Subjects consist of 220 patients. Twenty eight-day mortality was 40%.Significant prognostic factors indentified were admission source (medical (HR2.75; CI95%: 1.56 – 4.84), emergency surgery (HR 1.96; CI95%:0.99 – 3.90),Charlson comorbidity index > 2(HR 2.07; CI95%:1.32 – 3.23), and MSOFA score> 4 (HR 2.84; CI95% : 1.54 – 5.24). Prediction model developed has gooddiscrimination ability (AUC 0.844) and good calibration (Hosmer-Lemeshow testp 0.674). Based on the model mortality risk can be classified as low (score 0,mortality 5.4%), moderate (score 1 – 2.5, mortality 20.6%), and high (score > 2.5,mortality 73.6%).Conclusion. Medical and emergency surgery admission, Charlson comorbidityindex > 2, and MSOFA score > 4 were prognostic factors of mortality from latephase of severe sepsis in ICU at Dr.Cipto Mangunkusumo general hospital. Amodel has been developed to predict and classify mortality risk."

"Background: Community acquired pneumonia (CAP) in the elderly is still a major problem due to its high morbidity and mortality. There is considerable variability in ?the result of various studies on prognostic factors. The prognostic factors in Indonesia have not been identified.Methods: We performed a prospective cohort study on 147 elderly patients hospitalized with CAP in the internal medicine ward of Cipto Mangunkusumo National Central General Hospital, Jakarta from September 2002 to March 2003. We calculated the survival rate during hospitalize-tion. We used Cox proportional-hazard regression analysis to examine factors associated with mortality in the first 48 hours of hospitalization. .Results: There were 34 deaths (23.1) associated with CAP in 1471 person-days. The survival rate at day 5, 10 and 15 were 88.9%, 77.2 and 67.2% respectively. Severe. pneumonia, an serum albumin of d"3.5 g/dL, reducedconsciousness, temperature > 37.0"C, and a hemoglobin level of d" 9.0 g/dL demonstrated a tendency towards increased mortality rate. Other factors such as age, sex, immobilization, swollen disorders, co-morbidities, leukocyte count, and serum creatinine level demonstrated no significant relationship with mortality.Conclusion: Severe pneumonia, low serum albumin, decreased consciousness, high temperature and low hemoglobin level in the first 48 hours hospitalization were found to be worse prognostic factors. Early identification and modification of these factors are recommended."

"ABSTRAKTujuan: Penelitian ini bertujuan untuk mengetahui kesintasan hidup pasien kanker serviks dan faktor-faktor yang mempengaruhinya.Metode: Penelitian ini menggunakan desain kohort retrospektif dengan analisis kesintasan. Pasien kanker serviks yang didiagnosis di Rumah Sakit Cipto Mangunkusumo pada 1 Januari 2005 sampai 31 Desember 2006 dimasukkan dalam penelitian ini. Dilakukan pendataan tanggal dan umur saat diagnosis, tingkat pendidikan, stadium, jenis histopatologi, diferensiasi tumor, invasi limfovaskuler, jenis terapi, dan lengkapnya terapi. Jika pasien menjalani operasi, dinilai pula adanya tumor pada kelenjar getah bening(KGB) atau batas sayatan. Selanjutnya pasien diamati sampai minimal 5 tahun apakah pasien masih hidup. Kemudian dilakukan analisis kesintasan dengan metode Kaplan Meier. Faktor-faktor yang mempengaruhi kesintasan dinilai dengan analisis Cox regression.Hasil: Diperoleh 447 pasien kanker serviks dalam kajian ini. Didapatkan median survival keseluruhan pasien kanker serviks 1916 hari (63 bulan) dengan kesintasan hidup 5 tahun 52%. Faktor umur, pendidikan, jenis pembiayaan, ukuran tumor, dan adanya invasi limfovaskuler tidak menunjukkan adanya perbedaan kesintasan. Stadium III dan IV memiliki kesintasan hidup yang lebih rendah dengan Hazard Ratio 3.27 dan 6.44. Diferensiasi buruk dan terapi tidak lengkap memiliki kesintasan yang lebih rendah dengan HR 2.26 dan 2.22. Jenis histopatologi lain-lain memiliki kesintasan yang lebih rendah dengan HR 2.85, namun tidak menunjukkan perbedaan bermakna pada uji multivariat. Pada pasien yang menjalani operasi disertai adanya tumor pada KGB menunjukkan kesintasan yang lebih rendah dengan HR 12.01, sedangkan adanya tumor pada batas sayatan tidak menunjukkan perbedaan kesintasan yang bermakna. Jenis terapi pada stadium awal ataupun sradium lanjut tidak menunjukkan perbedaan pada uji multivariat.Kesimpulan: Median survival pasien kanker serviks adalah 63 bulan. Faktor-faktor yang berpengaruh secara independen terhadap kesintasan pasien kanker serviks adalah stadium, diferensiasi tumor, kelengkapan terapi, dan adanya tumor pada kelenjar getah bening.

---

ABSTRACTObjective: To find out of the probability of 5 years survival rate on cervical cancer patients and to identify the influencing factors.Methods: This is a retrospective cohort study. Cervical cancer patients treated at Cipto Mangunkusumo Hospital in 2005-2006 were selected. Demographic and clinical data were collected. Demographic data collected were diagnosis time, age, and education level. Clinical data collected were stage, histopathology, differentiation, lymphovascular invasion, and therapy. The appearance of the tumor on the specimen margin and lymphnodes was also noted in the patient underwent surgery. All the patients were followed up for minimal 5 years to know whether the patient was alive. Kaplan Meier methods was used to determine the survival rate probability and Cox regression analysis was used to assessed the factors influencing the cervical cancer survivalResult: A total of 447 cervical cancer patients was enrolled to this study. Median survival of these patients was 63 months and the overall 5-years survival probability was 52%. Age, education level, funding source, tumor size, and lymph-vascular invasion showed no significant differences on cervical cancer survival. Stage III and IV had lower survival probability (Hazard Ratio 3.27 and 6.44). Poor differentiated tumor and uncompleted therapy also had lower survival probability (HR 2.26 and 2.22). Histopathology of others had lower survival probability(HR 2.85), but wasn't significant on multivariate analysis. The presence of tumor on the cervical cancer specimen during operation showed worse survival probability (HR 12.01), otherwise the presence of tumor on specimen margin didn't show difference survival. Therapy types didn't showed any differences, either on early and advanced stage.Conclusion: Cervical cancer median survival was 63 months. Independent influencing factors in this study were cancer’s stage, tumor differentiation, therapy completeness, and the presence of the tumor on the pelvic lymph nodes specimen during operation."

"Latar Belakang: Limfoma Hodgkin merupakan keganasan yang mencakup 1% kasus kanker keseluruhan. Adapun overall survival (OS) pasien limfoma Hodgkin dalam lima tahun mencapai 90%. Namun, progression-free survival (PFS) limfoma Hodgkin hanya mencapai 70-90% dalam kurun waktu 25 bulan. Setelah mengalami progresivitas, pasien mengalami penurunan PFS setelah mendapat terapi lini kedua. Sehingga, perlu diketahui faktor-faktor prediktor yang mempengaruhi PFS pasien limfoma Hodgkin.Tujuan: Mengetahui faktor-faktor prognostik PFS dua tahun pasien limfoma Hodgkin. Metode: Penelitian ini menggunakan desain kohort retrospektif yang melibatkan pasien limfoma Hodgkin yang teregistrasi dari tahun 2011-2021 di Rumah Sakit Umum Pusat Nasional Dokter Cipto Mangunkusumo. Faktor-faktor prognostik yang diteliti adalah stratifikasi risiko, skor prognosis internasional, kadar trombosit, laktat dehidrogenase, indeks komorbiditas Charlson, dan waktu sejak diagnosis hingga terapi. Analisis multivariat terhadap PFS dua tahun dilakukan menggunakan model regresi Cox.Hasil: Terdapat 115 subjek yang disertakan dalam penelitian dengan median usia 29 tahun, kadar trombosit 393.000 sel/L, LDH 340 IU/L, dan waktu sejak diagnosis hingga terapi enam minggu. Sebagian besar subjek penelitian adalah kelompok stadium lanjut (53,91%), total skor prognosis internasional 0-3 (69,57%), dan total skor indeks komorbiditas Charlson 0-1 (75,65%). Angka PFS dua tahun pasien limfoma Hodgkin di RSCM sebesar 59,13%. Hasil analisis bivariat menunjukkan waktu sejak diagnosis hingga terapi yang tidak memiliki kemaknaan secara statistik dengan HR 0,83 (IK 95% 0,42-1,59, p=0,57). Analisis multivariat menghasilkan tiga faktor prognostik independen, yakni stadium lanjut (HR 7,85 IK 95% 3,01-20,47, p<0,01), trombosit >450.000 sel/L (HR 2,77 IK 95% 1,49-5,16, p<0,01), dan LDH baik 250-500 IU/L (HR 2,57 IK 95% 1,01-3,63, p=0,04) maupun >500 IU/L (HR 3,06 IK 95% 1,20-7,82, p=0,02). Sistem skor berdasarkan ketiga variabel tersebut memiliki diskriminasi yang baik (AUROC 0,879, IK 95% 0,816-0,942, p <0,01).Kesimpulan: Stadium lanjut, trombosit >450.000 sel/L, dan LDH 250 IU/L merupakan faktor-faktor prognostik PFS dua tahun pada pasien limfoma Hodgkin.

---

Background: Hodgkin's lymphoma is a malignancy that accounts for 1% of all cancer cases. The overall survival (OS) of Hodgkin's lymphoma patients in five years reaches 90%. However, progression-free survival (PFS) for Hodgkin's lymphoma only reaches 70-90% within 25 months. After experiencing progression, patients experienced a decrease in PFS after receiving second-line therapy. So, it is necessary to know the predictor factors that influence the PFS of Hodgkin's lymphoma patients.

Aim: To determine prognostic factors for two-year PFS in Hodgkin's lymphoma patients. Methods: This study used a retrospective cohort design involving Hodgkin's lymphoma patients registered from 2011-2021 at Dokter Cipto Mangunkusumo National General Hospital. The prognostic factors studied were risk stratification, international prognosis score, platelet levels, lactate dehydrogenase, Charlson comorbidity index, and time from diagnosis to therapy. Multivariate analysis of two-year PFS was performed using Cox regression models.

Results: There were 115 subjects included in the study with a median age of 29 years, platelet levels of 393,000 cells/L, LDH 340 IU/L, and time from diagnosis to therapy of six weeks. Most of the research subjects were in the advanced stage group (53.91%), the total international prognosis score was 0-3 (69.57%), and the total Charlson comorbidity index score was 0-1 (75.65%). The two-year PFS rate for Hodgkin's lymphoma patients at RSCM was 59.13%. The results of bivariate analysis showed that the time from diagnosis to therapy was not statistically significant with HR 0.83 (95% CI 0.42-1.59, p=0.57). Multivariate analysis yielded three independent prognostic factors, namely advanced stage (HR 7.85, 95% CI 3.01-20.47, p<0.01), platelets >450,000 cells/L (HR 2.77, 95% CI 1.49-5.16, p<0.01), and LDH either 250-500 IU/L (HR 2.57, 95% CI 1.01- 3.63, p=0.04) or >500 IU/L (HR 3.06 95% CI 1.20-7.82, p=0.02). The scoring system based on these three variables had good discrimination (AUROC 0.879, 95% CI 0.816- 0.942, p <0.01).

Conclusion: Advanced stage, platelets >450,000 cells/L, and LDH >250 IU/L are prognostic factors for two-year PFS in Hodgkin's lymphoma patients."